Management of Tuberculosis in Pregnancy
First-Line Treatment Regimen
- The American Thoracic Society recommends that the initial treatment regimen for pregnant women with tuberculosis should consist of isoniazid, rifampin, and ethambutol 1
- Treatment should be started without delay as untreated tuberculosis poses a greater risk to both mother and fetus than the medications 1
- Pyridoxine (vitamin B6) supplementation (25 mg/day) should be given to all pregnant women receiving isoniazid to prevent neurotoxicity 1
Medications to Avoid in Pregnancy
- The Centers for Disease Control and Prevention recommends that streptomycin and other aminoglycosides (kanamycin, amikacin) should be avoided during pregnancy as they can cause congenital deafness in approximately 17% of exposed fetuses 1
- The World Health Organization recommends that pyrazinamide is generally not recommended in pregnancy in the United States due to insufficient teratogenicity data, although international organizations do recommend its routine use 1, 2
- The American College of Obstetricians and Gynecologists recommends that fluoroquinolones should be avoided if possible during pregnancy due to their association with arthropathies in young animals 1
Duration of Treatment
- The American Thoracic Society recommends that if pyrazinamide is not included in the treatment regimen, the minimum duration of therapy should be 9 months 1
- For standard drug-susceptible tuberculosis, the 9-month regimen typically consists of isoniazid and rifampin throughout, with ethambutol in the initial phase until drug susceptibility is confirmed 1
Monitoring During Treatment
- Close monitoring of liver function is essential, as pregnancy does not increase the risk of TB progression but may increase vulnerability to isoniazid hepatotoxicity 2, 3
- Baseline liver function tests should be obtained, followed by regular monitoring, particularly during the first two months of treatment 4
Special Considerations
- The World Health Organization recommends that breastfeeding should not be discouraged for women being treated with first-line anti-tuberculosis drugs, as the small concentrations in breast milk do not produce toxic effects in the nursing infant 5
- However, drugs in breast milk should not be considered effective treatment for tuberculosis in the nursing infant 5
- For multidrug-resistant tuberculosis (MDR-TB), consultation with an expert in tuberculosis management is recommended, as treatment must be individualized based on susceptibility studies 1
Potential Complications and Management
- Termination of pregnancy is not medically indicated for women taking first-line anti-tuberculosis drugs 4
Post-Delivery Considerations
Antitubercular Treatment in Pregnancy
Recommended Treatment Approach
- For women with latent TB infection (LTBI) rather than active disease, some experts recommend delaying treatment until after the first trimester if progression risk is low, according to the Centers for Disease Control and Prevention (CDC) guidelines 6
- However, for HIV-infected pregnant women or those with recent TB exposure, LTBI treatment should not be delayed even in the first trimester, as recommended by the CDC 6
Monitoring and Treatment Adjustment
- Repeat liver function testing at 2, 4, and 8 weeks if using combination therapy, as suggested by the CDC guidelines 6
Special Considerations
- For contacts of isoniazid-resistant cases, consider rifampin-based regimens, as recommended by the CDC 6
High-Risk Patient Management
- Never delay treatment waiting for the second trimester in high-risk patients (HIV-infected, recent converters, or active disease), according to the CDC guidelines 6
Evidence‑Based Recommendations for Tuberculosis Management in Pregnancy
Contraindicated Antituberculosis Agents
- Streptomycin and all aminoglycosides (kanamycin, amikacin) are absolutely contraindicated in pregnancy because they cause congenital deafness in approximately 17 % of exposed fetuses【7】.
- Ethionamide and prothionamide are considered potentially teratogenic and should be avoided in pregnant patients【7】.
Monitoring and Drug‑Interaction Considerations
- Liver enzymes should be monitored closely during the first two months of therapy—specifically at weeks 2, 4, and 8—because pregnancy may increase susceptibility to isoniazid‑related hepatotoxicity【7】.
- Rifampin reduces the efficacy of combined oral contraceptives; alternative contraception methods must be discussed with the patient【7】.
- In patients receiving corticosteroids, the maintenance steroid dose should be doubled because rifampin induces hepatic enzymes that accelerate steroid metabolism【7】.
Breastfeeding and Pregnancy Reassurance
- Breastfeeding should be encouraged in women taking first‑line antituberculosis drugs (isoniazid, rifampin, ethambutol, ethylene‑diamines) because drug concentrations in breast milk are too low to cause toxicity in the infant【7】.
- Pregnancy is not an indication for termination when a woman is receiving rifampin or other first‑line antituberculosis medications【7】.
- No teratogenic effects have been demonstrated in humans for the first‑line agents isoniazid, rifampin, and ethambutol【7】.
- Standard first‑line treatment can be administered safely throughout all trimesters of pregnancy【7】.
Practical Treatment Pitfalls to Avoid
- Streptomycin must not be used even when drug resistance is suspected; alternative second‑line agents should be selected【7】.
- Pyridoxine (vitamin B6) supplementation is mandatory for all pregnant women receiving isoniazid to prevent peripheral neurotoxicity【7】.
Guideline Recommendations for First‑Line Antituberculosis Therapy in Pregnancy
Initial Treatment Regimen
- Pregnant patients with suspected or confirmed active tuberculosis should receive immediate therapy with isoniazid, rifampin, and ethambutol, together with pyridoxine 25 mg daily, because the maternal and fetal risks of untreated disease far outweigh medication risks. 8, 9, 10
- The three core drugs (INH, RIF, EMB) cross the placenta but have no documented teratogenic effects in humans. 8, 10
- Pyridoxine 25 mg daily is recommended for all pregnant women on isoniazid to prevent peripheral neurotoxicity. 8, 9
Use of Pyrazinamide
- In the United States, pyrazinamide is not routinely recommended during pregnancy due to insufficient teratogenicity data, despite endorsement by WHO and IUATLD. 8, 9, 10
- Some U.S. public‑health jurisdictions have used pyrazinamide in pregnancy without reported adverse events. 8, 9
- When pyrazinamide is omitted, the total treatment duration should be extended to at least 9 months (instead of the standard 6 months). 8
Contraindicated Medications
- Aminoglycosides (streptomycin, kanamycin, amikacin, capreomycin) must never be used during pregnancy. 8, 10
- Streptomycin exposure is associated with congenital deafness in approximately 17 % of fetuses, ranging from mild hearing loss to bilateral deafness. 8, 10
- Fluoroquinolones should be avoided when possible because of arthropathy risk observed in young animals, although they may be considered for essential treatment of drug‑resistant tuberculosis. 8, 10
- Ethionamide should be avoided because of reported nonspecific teratogenic effects. 8
Treatment Duration Without Pyrazinamide
- Recommended regimen: 2 months of INH + RIF + EMB, followed by 7 months of INH + RIF, for a total of 9 months of therapy. 8
Breastfeeding Guidance
- Breastfeeding is encouraged for women receiving INH, RIF, and EMB, as drug concentrations in breast milk are too low to cause infant toxicity. 8, 10
- Provide pyridoxine 25 mg daily to both the mother and the nursing infant when isoniazid is part of the regimen. 8
- Antituberculosis drugs present in breast milk do not provide therapeutic treatment for the infant; full therapeutic doses must be administered directly if the infant requires therapy. 8, 10